(24 Jul 2024)
RESTRICTION SUMMARY:
ASSOCIATED PRESS
Cape Town, South Africa – 23 July 2024
1. Wide of lab technicians sorting through sample bottles of blood tests at the Desmond Tutu Health Foundation
2. Close of sample bottles
3. SOUNDBITE (English) Thandeka Nkosi, clinical trials coordinator at the Desmond Tutu Health Foundation: ++STARTS ON SHOT 2 AND PARTIALLY OVERLAID WITH SHOT 4 AND 5++
"With the twice-yearly injectable, we see, we know that participants will be quite excited about it. Just purely because the injectable versus the pill. We’ve seen how adherence is not always the greatest when it comes to the pill, purely because of different reasons, time, ability to go and fetch those pills from the clinics. And so with the injectable and twice yearly this gives a participant more choice. Also in terms of the stigma, we know that when participants are on these pre-exposure prophylaxis pills, there is a sense of stigma where people think that they are HIV positive and not necessarily trying to prevent HIV."
4. Wide of pharmacist preparing to extract injectables
5. Various of pharmacist extracting Lenacapivir from the vial with a syringe
6. Wide of street scene in Masiphumelele township
7. SOUNDBITE (English) Olwethu Kemele, community field worker: ++STARTS ON SHOT 6 AND PARTIALLY OVERLAID WITH SHOT 8++
"The injectable will be really great for the young girls, because they will come in like each and every six months, compared to taking a pill each and every day. So, it will be almost like when you come in for your contraception, so for them, it will be really great. It will boost the number of people who are coming in to take the injection, so it will lower the rate of HIV in the community."
8. Wide of man with trolley as people walk by
9. Wide of street scene of Masiphumelele township
STORYLINE:
A study has shown that twice-yearly injections of a drug used to treat AIDS have been 100% effective in preventing new HIV infections in young women.
The study results were presented at a medical conference in Munich, Germany on Wednesday.
The injections could provide a new option in the battle against the spread of HIV.
The injectable is made by the U.S. drugmaker Gilead and sold as Sunlenca.
So far, it has only been approved to treat HIV, not prevent it.
But researchers reported there were no HIV infections in the group of girls and young women who received the injections at various trial locations in South Africa and Uganda.
In a group given daily pills that can protect against HIV infection, roughly 2% were found to have still been infected with the virus.
The trial consisted of about 5,000 girls and young women.
The new injections could be especially important for the fight against HIV in parts of the developing world, like in Cape Town, South Africa, one of the locations for the trial.
South Africa has the highest number of people living with HIV in the world.
Health workers involved in the trial in Cape Town say the injections every six months have many advantages, including being easier for women than having to take daily pills.
They say injections may also reduce the stigma sometimes attached with going to a clinic regularly to collect pills or having to explain to partners why you are taking HIV prevention medication.
Experts are excited about the Sunlenca shots, but are concerned Gilead hasn’t yet agreed on an affordable price for those who need them the most, especially in poorer countries.
As an HIV treatment, the twice-a-year drug costs more than $40,000 in the U.S., although what individuals pay varies.
Find out more about AP Archive: http://www.aparchive.com/HowWeWork
Twitter: https://twitter.com/AP_Archive
Facebook: https://www.facebook.com/APArchives
Instagram: https://www.instagram.com/APNews/
You can license this story through AP Archive: http://www.aparchive.com/metadata/youtube/41a1e43254914655870c1d932681602d
Author: AP Archive
Go to Source
News post in July 29, 2024, 3:04 pm.
Visit Our Sponsor’s:
News Post In – News
